Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
- Conditions
- First Posted Date
- 2004-03-25
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Ligand Pharmaceuticals
- Registration Number
- NCT00006345
- Locations
- ๐บ๐ธ
Veterans Affairs Medical Center - Miami, Miami, Florida, United States
๐บ๐ธWashington University School of Medicine, Saint Louis, Missouri, United States
๐บ๐ธRush Cancer Institute, Chicago, Illinois, United States
S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2004-03-16
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 19
- Registration Number
- NCT00005834
- Locations
- ๐บ๐ธ
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
๐บ๐ธJonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
๐บ๐ธVeterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
Isotretinoin Plus Dexamethasone in Treating Patients With Multiple Myeloma
- Conditions
- First Posted Date
- 2004-03-11
- Last Posted Date
- 2013-07-10
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00021359
- Locations
- ๐บ๐ธ
Hunterdon Regional Cancer Center, Flemington, New Jersey, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
๐บ๐ธFox Chase Cancer Center at Virtua Memorial Hospital Burlington County, Mount Holly, New Jersey, United States
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 849
- Registration Number
- NCT00078949
- Locations
- ๐จ๐ฆ
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
๐บ๐ธIndiana University Medical Center, Indianapolis, Indiana, United States
๐บ๐ธUniversity of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Registration Number
- NCT00002531
- Locations
- ๐ฉ๐ช
Klinikum der J.W. Goethe Universitaet, Frankfurt, Germany
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Hannover Medical School
- Registration Number
- NCT00002532
- Locations
- ๐ฉ๐ช
Medizinische Hochschule Hannover, Hannover, Germany
Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma
- Conditions
- First Posted Date
- 2004-01-22
- Last Posted Date
- 2013-06-26
- Lead Sponsor
- University of Tennessee
- Registration Number
- NCT00003007
- Locations
- ๐บ๐ธ
William F. Bowld Hospital, Memphis, Tennessee, United States
๐บ๐ธMethodist Healthcare - Hospital of Memphis, Memphis, Tennessee, United States
๐บ๐ธBaptist Memorial Hospital, Memphis, Tennessee, United States
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 3154
- Registration Number
- NCT00075725
- Locations
- ๐บ๐ธ
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
๐บ๐ธRush University Medical Center, Chicago, Illinois, United States
๐บ๐ธChildren's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102)
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 710
- Registration Number
- NCT00075829
- Locations
- ๐บ๐ธ
DFCI/Brigham & Women's, Boston, Massachusetts, United States
๐บ๐ธFred Hutchinson Cancer Research Center, Seattle, Washington, United States
๐บ๐ธUniversity of Minnesota, Minneapolis, Minnesota, United States
Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
- Conditions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT00074178
- Locations
- ๐บ๐ธ
Oregon Health & Science University Cancer Institute, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.